Ira Mellman

Ira Mellman, PhD is Vice President of Cancer Immunology at Genentech and Head of the IIIA (Immunology, Infectious Disease & Ophthalmology) Research division. Before joining Genentech, he was Professor and Chair of Cell Biology at Yale University School of Medicine, where he built a distinguished academic career studying membrane trafficking, endosomal biology, and dendritic cell function. At Genentech, Dr. Mellman has been the scientific architect of the cancer immunology and checkpoint immunotherapy program, playing a central role in the development of atezolizumab (Tecentriq), the first FDA-approved anti-PD-L1 antibody, for urothelial carcinoma and non-small cell lung cancer. He is widely known for articulating the "cancer immunity cycle" — a conceptual framework published in Immunity (2013, with Daniel Chen) that describes the sequential steps from tumor antigen release through T cell priming, trafficking, infiltration, and tumor killing, and explains how tumors can break this cycle at multiple points to evade immune destruction. This framework has profoundly influenced how the field thinks about immunotherapy combination strategies: targeting different steps in the cycle to restore anti-tumor immunity. Dr. Mellman has been a major voice bridging basic immunology and cancer drug development, and has contributed to the scientific underpinnings of multiple approved checkpoint inhibitors and combination approaches. He has published more than 300 peer-reviewed papers and is a member of the National Academy of Sciences.